AbbVie drops CytomX partnership, leaving PhII program in the air

28 Mar 2023
endpts.com
License out/inClinical ResultADCImmunotherapyPhase 2
AbbVie is winding down its collaboration with CytomX seven years after first embarking on a search for conditionally activated cancer immunotherapy programs. CytomX will be weighing its options for CX-2029, a CD71-directed antibody-drug conjugate, after AbbVie decided not to advance the drug into additional studies, the biotech disclosed in its quarterly update. The Big Pharma partner also served notice to terminate their licensing deal, which dates back to 2016, on the same day. While CytomX has seen a number of clinical setbacks over the years, its technology is still garnering the attention of big-name partners, including, most recently, Regeneron . Updated Phase II data for CX-2029, released in January, suggested CX-2029 spurred a 21% objective response rate among a group of heavily pre-treated patients with squamous esophageal cancer. The ORR was 10% in squamous non-small cell lung cancer. The adverse event profile was consistent with what was seen in Phase I, CytomXCytomX added, with anemia being the most common side effect — experienced by 82.6% of patients in the trial. When they first teamed up, the companies described CD71 — the transferrin receptor — as an attractive cancer target that was, however, also present in normal cells. CytomX’s Probody technology promises to circumvent that problem by selectively delivering a cytotoxic payload to the tumor site. AbbVie paid $30 million upfront to ink the deal and handed over another $15 million in milestones in 2017 for the start of toxicology studies.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.